Lymphoma Australia inofara kukuzivisa iwe kuti varwere vanokodzera vane Mycosis Fungoides - rudzi rwecutaneous (ganda) T-cell lymphoma zvino iva neimwe nzira yokurapa nayo. Kubva 1 Mbudzi 2024, LEDAGA® gel inowanikwa paAustralia's Pharmaceutical Benefits Scheme (PBS). Iri idanho rakakura kumberi kune vanhu vakuru vane Mycosis Fungoides. Mushonga unoshanda weiyi nyaya yekurapa ndeye Chlormethine Hydrochloride, inova alkylating agent. Izvi zvinoreva kuti imhando yechemotherapy mune fomu yegel uye inoiswa zvakananga kune ganda rakabatwa.
Kuve nekurapa uku kwakanyorwa paPBS kunopa imwe nzira inokwanisika uye iri nyore kune varwere vanokodzera kubata mamiriro avo.
Kuti vakwanise kurapwa uku, varwere vanofanirwa kuita mamwe maitiro:
- chirwere chinofanira kunge chiri padanho rekutanga (IA, IB, kana IIA), yakasimbiswa nebiopsy
- inobata chete nzvimbo shoma yemuviri (kusvika ku25%)
- murwere anofanira kunge ari pamusoro pemakore 18.
Chete madermatologists kana hematologists vanogona kuzvinyorera, nemvumo inobvumira kusvika kumasvondo mana ekurapwa padanho rega rega.
Vanamazvikokota vezvehutano vanokurudzirwa kuti vajairane neruzivo rweLEDAGA's®, kusanganisira mashandisirwo nemazvo nekuchengetedza. Rumwe ruzivo runogona kuwanikwa mune zvinyorwa zvepamutemo zvechigadzirwa. Iyi ibudiriro inovimbisa yekuvandudza kutarisirwa uye kuwanikwa kweavo vanogara neMF-CTCL.
